在治疗EGFR exon20ins突变高级NSCLC的新进展
Chun Yuan1,2,3, Jun-Yan Yu1,2,3, Chuan-Xiu Zeng1,2,3
1Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin, China.
American journal of cancer research
|May 15, 2025
概括
在非小细胞肺癌 (NSCLC) 中表皮生长因子受体 (EGFR) 异构20插入突变对标准治疗反应不佳. 新型向疗法正在成为这些具有挑战性的病例的有希望的选择.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮表皮生长因子受体 (EGFR) 异位子20插入 (ex20ins) 突变是非小细胞肺癌 (NSCLC) 的一个独特的子集,占EGFR变化的4%-12%.
- 这些突变是EGFR变异的第三个最常见的变异,仅次于19号外显子删除和21号外显子L858R替代.
- 像EGFR氨酸激酶抑制剂 (TKIs),化疗和免疫疗法等传统疗法在具有EGFR ex20ins突变的晚期NSCLC患者中表现出有限的疗效.
研究的目的:
- 审查针对特定针对NSCLCEGFR ex20ins突变的向治疗的最新研究.
- 分析新兴向剂的作用机制.
- 评估临床试验结果和综合证据,以优化患者管理.
主要方法:
- 对EGFR ex20ins突变的向疗法进行当前文献的系统审查.
- 对新型治疗剂的临床前和临床数据的分析.
- 整合证据以告知临床策略.
主要成果:
- 新兴的向药物显示出克服与EGFR ex20ins突变相关的抵抗机制的前景.
- 临床试验表明,在精选的患者群体中,应答率和无进展生存率得到改善.
- 了解ex20ins内的特定突变亚型可以指导个性化治疗选择.
结论:
- 对于EGFR ex20ins-突变NSCLC的有效治疗方法存在重大未满足的需求.
- 向疗法在这个患者群体中代表了精准医学的一个有希望的途径.
- 进一步的研究和临床试验对于建立最佳治疗策略至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K